April 29 (Reuters) - The U.S. Food and Drug Administration (FDA) on Monday published the final rule to ensure safety and effectiveness of laboratory developed tests (LDTs), which are designed, manufactured and used within a clinical laboratory. (Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini Ganguli)
Laboratory Corporation of America Holdings
Equities
LH
US50540R4092
Healthcare Facilities & Services
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
213.2 USD | +0.95% | +5.75% | -6.19% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
213.2 USD | +0.95% | +5.75% | 17.97B | ||
140.8 USD | +1.16% | +3.41% | 15.64B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.19% | 17.97B | |
-28.75% | 70.63B | |
+2.04% | 27.05B | |
+2.32% | 17.58B | |
+2.10% | 15.64B | |
+7.06% | 13.55B | |
+10.80% | 13.41B | |
+71.31% | 13.18B | |
+75.96% | 12.99B | |
+1.87% | 12.59B |
- Stock Market
- Equities
- LH Stock
- News Laboratory Corporation of America Holdings
- US FDA publishes final rule for laboratory developed tests